Search

everythinglearnresearchcommunity

for

Search:↓

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

The new clinical trial design is promising but needs real-world trials to test its effectiveness and possible enhancements.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

Promising cancer treatments were found, but the manufacturer closed.

Men have more tryptophan in their hair than women, and it increases with age and is higher in darker and grey or white hair.

MK-5108 is safe and shows potential against tumors, especially alone.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.

Baricitinib was effective in treating alopecia areata in two major trials.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

Alisertib was found to be an effective and tolerable treatment for children with recurrent brain tumors.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

The treatment combination is effective and generally safe for lung cancer.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.

Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

Patients with advanced breast cancer prioritize quality of life, overall survival, and progression-free survival in treatment decisions.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

Hair regrowth improved, but quality of life did not.

The document's conclusion cannot be provided because the content is not available.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.